Quick Answer
Ginkgo Bioworks Holdings, Inc. reported R&D Expense of $243.77 million for fiscal year 2025.
Ginkgo Bioworks Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $243.77M | -42.5% |
| 2024 | $424.06M | -27.0% |
| 2023 | $580.62M | -44.8% |
| 2022 | $1.05B | -8.4% |
| 2021 | $1.15B | +619.6% |
| 2020 | $159.77M | +65.9% |
| 2019 | $96.30M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $69.35M | -9.9% | +29.9% |
| June 30, 2025 | $53.37M | -60.2% | -24.7% |
| March 31, 2025 | $70.92M | -48.0% | -7.9% |
| September 30, 2024 | $77.01M | -50.8% | -42.6% |
| June 30, 2024 | $134.22M | -7.0% | -1.6% |
| March 31, 2024 | $136.46M | -16.1% | -12.9% |
| September 30, 2023 | $156.66M | -40.1% | +8.6% |
| June 30, 2023 | $144.28M | -50.3% | -11.3% |
- Ginkgo Bioworks Holdings, Inc. showed a decrease of -42.5% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Ginkgo Bioworks Holdings, Inc.’s r&d expense has grown by 153.1% (from $96.30 million to $243.77 million).
- The most recent figure is from Ginkgo Bioworks Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: